Association of Soluble Receptor for Advanced Glycation End Products Levels with Hypertensive Albuminuria

Author(s): Huan Zheng, Lingyan Yuan, Nanzi Xie, Huifeng Xu, Xiaoyun Xie, Ming Luo

Journal Name: Current Vascular Pharmacology

Volume 13 , Issue 2 , 2015

Become EABM
Become Reviewer


Objective: Soluble receptor for advanced glycation end products (sRAGE) levels have been found to be decreased in chronic inflammatory diseases including atherosclerosis, hypertension and renal failure. This study evaluated the relationship between sRAGE concentrations and urinary albumin excretion in patients with essential hypertension. Methods: A total of 200 consecutive patients with essential hypertension were enrolled and were divided into 3 groups. Results: Plasma sRAGE levels were significantly lower in hypertensive patients with micro- or macroalbuminuria compared with those in hypertensive patients with normoalbuminuria, and the values in the macroalbuminuria group were even lower than in the microalbuminuria group (128.6±24.2, 244.6±37.6313.6±30.7 pg/ml respectively). In addition, plasma sRAGE level was an independent determinant of log urinary albumin excretion in patients with essential hypertension (β=0.267, P<0.05). Conclusions: sRAGE may play a role in the pathogenic processes that link albuminuria, chronic inflammation and oxidative stress in hypertensive patients.

Keywords: Albuminuria, hypertension, receptor for advanced glycation end products.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Page: [259 - 264]
Pages: 6
DOI: 10.2174/1570161111666131209143650
Price: $65

Article Metrics

PDF: 21